Evaluating tissue plasminogen activator (tPA) in dialysis catheter dysfunction: A focus on fibrin sheath and risk factors.

ABSTRACT:

Background

Hemodialysis catheter dysfunction can arise from fibrin sheath formation, leading to impaired patency and compromised treatment. Tissue plasminogen activator (tPA) is an emerging treatment option to restore catheter patency. This study evaluated the efficacy of tPA therapy and explored clinical and demographic risk factors for catheter dysfunction.

Methods

This retrospective study included 42 hemodialysis patients with central venous catheters (CVCs) at Imam Reza Hospital, Tabriz, Iran (2020-2023). Inclusion criteria were inability to withdraw blood or inadequate flow in one or both catheter lumens, confirmed by venographic evidence of fibrin sheath formation. Patients received 2 mg tPA in 2 ml saline with a 30-min dwell time. Data on patient demographics,

SUBMITTER: Jalili J 

PROVIDER: S-EPMC12391680 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature